Verici Dx (LON:VRCI) Trading 4.4% Higher – Still a Buy?

Verici Dx plc (LON:VRCI)’s stock price rose 4.4% on Thursday . The stock traded as high as GBX 2.48 ($0.03) and last traded at GBX 2.48 ($0.03). Approximately 215,225 shares changed hands during trading, a decline of 36% from the average daily volume of 333,685 shares. The stock had previously closed at GBX 2.38 ($0.03).

Verici Dx Price Performance

The company has a quick ratio of 8.49, a current ratio of 4.54 and a debt-to-equity ratio of 4.65. The stock has a market capitalization of £7.88 million, a PE ratio of -162.50 and a beta of 1.59. The stock’s 50-day moving average is GBX 3.07 and its 200 day moving average is GBX 5.43.

About Verici Dx

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.